Patent foramen ovale closure: past, present and future

References

• Meier B, Lock JE. Contemporary management of patent foramen ovale. Circulation107(1), 5–9 (2003).
   PubMed Web of Science ®Google Scholar
• Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin. Proc.59(1), 17–20 (1984).
   PubMed Web of Science ®Google Scholar
• Hanley PC, Tajik AJ, Hynes JK et al. Diagnosis and classification of atrial septal aneurysm by two-dimensional echocardiography: report of 80 consecutive cases. J. Am. Coll. Cardiol.6(6), 1370–1382 (1985).
   PubMed Web of Science ®Google Scholar
• Silver MD, Dorsey JS. Aneurysms of the septum primum in adults. Arch. Pathol. Lab. Med.102(2), 62–65 (1978).
   PubMed Web of Science ®Google Scholar
• Agmon Y, Khandheria BK, Meissner I et al. Frequency of atrial septal aneurysms in patients with cerebral ischemic events. Circulation99(15), 1942–1944 (1999).
   PubMed Web of Science ®Google Scholar
• Wahl A, Windecker S, Meier B. Percutaneous closure of patent formamen ovale with the amplatzer PFO occluder: European experience. In: Interventional Cardiology. Percutaneous Noncoronary Intervention. Hermann HC (Ed.). Humana Press, NJ, USA 143–160 (2005).
   Google Scholar
• Webster MW, Chancellor AM, Smith HJ et al. Patent foramen ovale in young stroke patients. Lancet2(8601), 11–12 (1988).
   PubMed Web of Science ®Google Scholar
• Knauth M, Ries S, Pohimann S et al. Cohort study of multiple brain lesions in sport divers: role of a patent foramen ovale. BMJ314(7082), 701–705 (1997).
   PubMed Web of Science ®Google Scholar
• Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet356(9242), 1648–1651 (2000).
   PubMed Web of Science ®Google Scholar
• Rosamond W, Flegal K, Friday G et al. Heart disease and stroke statistics – 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation115(5), e69–e171 (2007).
   PubMed Web of Science ®Google Scholar
• Sacco RL, Ellenberg JH, Mohr JP et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann. Neurol.25(4), 382–390 (1989).
   PubMed Web of Science ®Google Scholar
• Meissner I, Khandheria BK, Heit JA et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J. Am. Coll. Cardiol.47(2), 440–445 (2006).
   PubMed Web of Science ®Google Scholar
• Di Tullio MR, Sacco RL, Sciacca RR, Jin Z, Homma S. Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J. Am. Coll. Cardiol.49(7), 797–802 (2007).
   PubMed Web of Science ®Google Scholar
• Lechat P, Mas JL, Lascault G et al. Prevalence of patent foramen ovale in patients with stroke. N. Engl. J. Med.318(18), 1148–1152 (1988).
   PubMed Web of Science ®Google Scholar
• Steiner MM, Di Tullio MR, Rundek T et al. Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke29(5), 944–948 (1998).
   PubMed Web of Science ®Google Scholar
• Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case–control studies. Neurology55(8), 1172–1179 (2000).
   PubMed Web of Science ®Google Scholar
• De Castro S, Cartoni D, Fiorelli M et al. Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke31(10), 2407–2413 (2000).
   PubMed Web of Science ®Google Scholar
• Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation105(22), 2625–2631 (2002).
   PubMed Web of Science ®Google Scholar
• Schneider B, Hanrath P, Vogel P, Meinertz T. Improved morphologic characterization of atrial septal aneurysm by transesophageal echocardiography: relation to cerebrovascular events. J. Am. Coll. Cardiol.16(4), 1000–1009 (1990).
   PubMed Web of Science ®Google Scholar
• Homma S, Di Tullio MR, Sacco RL, Mihalatos D, Li Mandri G, Mohr JP. Characteristics of patent foramen ovale associated with cryptogenic stroke. A biplane transesophageal echocardiographic study. Stroke25(3), 582–586 (1994).
   PubMed Web of Science ®Google Scholar
• Mas JL, Arquizan C, Lamy C et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N. Engl. J. Med.345(24), 1740–1746 (2001).
   PubMed Web of Science ®Google Scholar
• Windecker S, Wahl A, Nedeltchev K et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J. Am. Coll. Cardiol.44(4), 750–758 (2004).
   PubMed Web of Science ®Google Scholar
• Thanopoulos BV, Dardas PD, Karanasios E, Mezilis N. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke. Catheter. Cardiovasc. Interv.68(5), 741–746 (2006).
   PubMed Web of Science ®Google Scholar
• Boureau F, Joubert JM, Lasserre V, Prum B, Delecoeuillerie G. Double-blind comparison of an acetaminophen 400 mg–codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia, 14(2), 156–161 (1994).
   Google Scholar
• Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology44(6 Suppl. 4), S17–S23 (1994).
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Migraine. Lancet363(9406), 381–391 (2004).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Hamelsky SW, Stewart WF. Epidemiology and impact of headache. In: Wolff's headache and other head pain. Silberstein SD, Lipton RB, Dalessio DJ (Eds.) Oxford University Press, NY, USA 85–107 (2001).
   Google Scholar
• Badia X, Magaz S, Gutierrez L, Galvan J. The burden of migraine in Spain: beyond direct costs. Pharmacoeconomics22(9), 591–603 (2004).
   PubMed Web of Science ®Google Scholar
• Schwerzmann M, Nedeltchev K, Meier B. Patent foramen ovale closure: a new therapy for migraine. Catheter. Cardiovasc. Interv.69(2), 277–284 (2007).
   PubMed Web of Science ®Google Scholar
• Anzola GP, Magoni M, Guindani M, Rozzini L, Dalla Volta G. Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology52(8), 1622–1625 (1999).
   PubMed Web of Science ®Google Scholar
• Schwerzmann M, Nedeltchev K, Lagger F et al. Prevalence and size of directly detected patent foramen ovale in migraine with aura. Neurology65(9), 1415–1418 (2005).
   PubMed Web of Science ®Google Scholar
• Anzola GP, Morandi E, Casilli F, Onorato E. Different degrees of right-to-left shunting predict migraine and stroke: data from 420 patients. Neurology66(5), 765–767 (2006).
   PubMed Web of Science ®Google Scholar
• Lamy C, Giannesini C, Zuber M et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. Stroke33(3), 706–711 (2002).
   PubMed Web of Science ®Google Scholar
• Sztajzel R, Genoud D, Roth S, Mermillod B, Le Floch-Rohr J. Patent foramen ovale, a possible cause of symptomatic migraine: a study of 74 patients with acute ischemic stroke. Cerebrovasc. Dis.13(2), 102–106 (2002).
   PubMed Web of Science ®Google Scholar
• Ramadan NM, Schultz LL, Gilkey SJ. Migraine prophylactic drugs: proof of efficacy, utilization and cost. Cephalalgia17(2), 73–80 (1997).
   Google Scholar
• Bridges ND, Hellenbrand W, Latson L, Filiano J, Newburger JW, Lock JE. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation86(6), 1902–1908 (1992).
   PubMed Web of Science ®Google Scholar
• Khositseth A, Cabalka AK, Sweeney JP et al. Transcatheter Amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism. Mayo Clin. Proc.79(1), 35–41 (2004).
   PubMed Web of Science ®Google Scholar
• Chatterjee T, Petzsch M, Ince H et al. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism. J. Interv. Cardiol.18(3), 173–179 (2005).
   PubMedGoogle Scholar
• Alameddine F, Block PC. Transcatheter patent foramen ovale closure for secondary prevention of paradoxical embolic events: Acute results from the FORECAST registry. Catheter. Cardiovasc. Interv.62(4), 512–516 (2004).
   PubMed Web of Science ®Google Scholar
• Kiblawi FM, Sommer RJ, Levchuck SG. Transcatheter closure of patent foramen ovale in older adults. Catheter. Cardiovasc. Interv.68(1), 136–143 (2006).
   PubMed Web of Science ®Google Scholar
• Dowson A. Migraine Intervention with STARFlex Technology (MIST) Trial. In: American College of Cardiology. Atlanta, GA, USA (2006)
   Google Scholar
• Sigler M, Jux C. Biocompatibility of septal defect closure devices. Heart (2006).
   Google Scholar
• Sherman JM, Hagler DJ, Cetta F. Thrombosis after septal closure device placement: a review of the current literature. Catheter. Cardiovasc. Interv.63(4), 486–489 (2004).
   PubMed Web of Science ®Google Scholar
• Krumsdorf U, Ostermayer S, Billinger K et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J. Am. Coll. Cardiol.43(2), 302–309 (2004).
   PubMed Web of Science ®Google Scholar
• Jux C, Bertram H, Wohlsein P, Bruegmann M, Paul T. Interventional atrial septal defect closure using a totally bioresorbable occluder matrix: development and preclinical evaluation of the BioSTAR device. J. Am. Coll. Cardiol.48(1), 161–169 (2006).
   PubMed Web of Science ®Google Scholar
• Jux C, Wohlsein P, Bruegmann M, Zutz M, Franzbach B, Bertram H. A new biological matrix for septal occlusion. J. Interv. Cardiol.16(2), 149–152 (2003).
   PubMedGoogle Scholar
• Mullen MJ, Hildick-Smith D, De Giovanni JV et al. BioSTAR Evaluation STudy (BEST): a prospective, multicenter, Phase I clinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts. Circulation114(18), 1962–1967 (2006).
   PubMed Web of Science ®Google Scholar
• Billinger K, Ostermayer S, Carminati M et al. HELEX Septal Occluder for transcatheter closure of patent foramen ovale: multicenter experience. EuroInterv.1, 465–471 (2006).
   PubMedGoogle Scholar
• Buscheck F, Sievert H, Kleber F et al. Patent foramen ovale using the Premere device: the results of the CLOSEUP trial. J. Interv. Cardiol.19(4), 328–333 (2006).
   PubMedGoogle Scholar
• Spies C, Strasheim R, Timmermanns I, Schraeder R. Patent foramen ovale closure in patients with cryptogenic thrombo-embolic events using the Cardia PFO occluder. Eur. Heart J.27(3), 365–371 (2006).
   PubMed Web of Science ®Google Scholar
• Spies C, Doshi R, Timmermanns I, Schrader R. Closure of patent foramen ovale in patients with cryptogenic stroke or tia with the new intrasept-occluder. Catheter. Cardiovasc. Interv.69(6), S17 (2007).
   Google Scholar
• Skowasch M, Reschke M, Leetz M, Sievert H. Non-implant closure of patent foramen ovale: first in human results. Am. J. Cardiol.96(7 Suppl. 1), 49H (2005).
   Google Scholar